Keywords: ucb, shares, fall, fda, rejects, vimpat, dnp

UCB shares fall 8.3% as FDA rejects Vimpat for DNP

Article | 04 August 2008

• Print This

Shares in UCB dropped 8.3% to to 21.44 euros on July 30, after the Belgian drugmaker received a "not-approvable" letter from the US ...

Enjoying this article? To continue reading you need to login or subscribe.